Dr Nicholas Reed

  • Honorary Professor (Institute of Cancer Sciences)

Cancer Sci & Molecular Pathology, Alexander Stone Building

Publications

List by: Type | Date

Jump to: 2015 | 2012 | 2011 | 2010 | 2008
Number of items: 19.

2015

Rutherford, M.A., Rankin, A.J. , Yates, T.M., Mark, P.B. , Perry, C.G., Reed, N.S. and Freel, E.M. (2015) Management of metastatic phaeochromocytoma and paraganglioma: use of Iodine-131-meta-iodobenzylguanidine (131I-MIBG) therapy in a tertiary referral centre. QJM: An International Journal of Medicine, 108(5), pp. 361-368. (doi: 10.1093/qjmed/hcu208) (PMID:25267727)

2012

Brundage, M. et al. (2012) Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial. Annals of Oncology, 23(8), pp. 2020-2027. (doi: 10.1093/annonc/mdr583)

Verheijen, R.H.M., Cibula, D., Zola, P. and Reed, N. (2012) Cancer antigen 125: lost to follow-up? A European Society of Gynaecological Oncology consensus statement. International Journal of Gynecological Cancer, 22(1), pp. 170-174. (doi: 10.1097/IGC.0b013e318226c636)

Casado, A. et al. (2012) EORTC Gynecological Cancer Group on the frontline of practice-changing clinical trials. European Journal of Cancer Supplements, 10(1), pp. 66-75. (doi: 10.1016/S1359-6349(12)70013-7)

Cowan, C.C., Hutchison, C., Cole, T., Barry, S.J.E. , Paul, J. , Reed, N.S. and Russell, J.M. (2012) A randomised double-blind placebo-controlled trial to determine the effect of cranberry juice on decreasing the incidence of urinary symptoms and urinary tract infections in patients undergoing radiotherapy for cancer of the bladder or cervix. Clinical Oncology, 24(2), e31-e38. (doi: 10.1016/j.clon.2011.05.009)

Penninckx, B., Van de Voorde, W.M., Casado, A., Reed, N., Moulin, C. and Karrasch, M. (2012) A systemic review of toxic death in clinical oncology trials: an Achilles’ heel in safety reporting revisited. British Journal of Cancer, 107(1), pp. 1-6. (doi: 10.1038/bjc.2012.252)

Viswanathan, A.N. et al. (2012) International brachytherapy practice patterns: a survey of the Gynecologic Cancer Intergroup (GCIG). International Journal of Radiation Oncology, Biology, Physics, 82(1), pp. 250-255. (doi: 10.1016/j.ijrobp.2010.10.030)

2011

Cibula, D. et al. (2011) Training in bowel and upper abdominal surgery in gynaecological oncology. International Journal of Gynecological Cancer, 21(7), pp. 1264-1265. (doi: 10.1097/IGC.0b013e3182208141)

Kurtz, J. E. et al. (2011) Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study. Annals of Oncology, 22(11), pp. 2417-2423. (doi: 10.1093/annonc/mdr001)

Lee, C. K. et al. (2011) Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. British Journal of Cancer, 105(3), pp. 360-365. (doi: 10.1038/bjc.2011.256)

Medley, L., Morel, A. N., Farrugia, D., Reed, N., Hayward, N., Davies, J. M., Kirichek, O., Thakker, R.V. and Talbot, D. C. (2011) Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours. British Journal of Cancer, 104(7), pp. 1067-1070. (doi: 10.1038/bjc.2011.76)

Reed, N.S. and Harrand, R.L. (2011) Counterpoint: The role of adjuvant radiation in endometrial cancer. Inside, outside, or not at all? Brachytherapy, 10(1), pp. 4-6. (doi: 10.1016/j.brachy.2010.11.001)

Reed, N.S. and Harrand, R.L. (2011) Rebuttal to Drs. Nout and Creutzberg. Brachytherapy, 10(1), p. 8. (doi: 10.1016/j.brachy.2010.11.004)

Rustin, G. et al. (2011) A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer. Annals of Oncology, 22(11), pp. 2411-2416. (doi: 10.1093/annonc/mdq780)

Shrimali, R.K., Correa, P.D. and Reed, N.S. (2011) Dose-dense and dose-intense chemotherapy for small cell ovarian cancer: 2 cases and review of literature. Medical Oncology, 28(3), pp. 766-770. (doi: 10.1007/s12032-010-9509-0)

Vergote, I., Trope, C. G., Amant, F., Ehlen, T., Reed, N.S. and Casado, A. (2011) Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer. Journal of Clinical Oncology, 29(31), pp. 4076-4078. (doi: 10.1200/JCO.2011.36.9785)

Zweifel, M. et al. (2011) Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Annals of Oncology, 22(9), pp. 2036-2041. (doi: 10.1093/annonc/mdq708)

2010

Vergote, I. et al. (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. New England Journal of Medicine, 363(10), pp. 943-953. (doi: 10.1056/NEJMoa0908806)

2008

Reed, N.Z. et al. (2008) Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European organisation for research and treatment of cancer gynaecological cancer group study (protocol 55874). European Journal of Cancer, 44(6), pp. 808-818. (doi: 10.1016/j.ejca.2008.01.019)

This list was generated on Mon Sep 27 16:24:45 2021 BST.
Jump to: Articles
Number of items: 19.

Articles

Rutherford, M.A., Rankin, A.J. , Yates, T.M., Mark, P.B. , Perry, C.G., Reed, N.S. and Freel, E.M. (2015) Management of metastatic phaeochromocytoma and paraganglioma: use of Iodine-131-meta-iodobenzylguanidine (131I-MIBG) therapy in a tertiary referral centre. QJM: An International Journal of Medicine, 108(5), pp. 361-368. (doi: 10.1093/qjmed/hcu208) (PMID:25267727)

Brundage, M. et al. (2012) Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial. Annals of Oncology, 23(8), pp. 2020-2027. (doi: 10.1093/annonc/mdr583)

Verheijen, R.H.M., Cibula, D., Zola, P. and Reed, N. (2012) Cancer antigen 125: lost to follow-up? A European Society of Gynaecological Oncology consensus statement. International Journal of Gynecological Cancer, 22(1), pp. 170-174. (doi: 10.1097/IGC.0b013e318226c636)

Casado, A. et al. (2012) EORTC Gynecological Cancer Group on the frontline of practice-changing clinical trials. European Journal of Cancer Supplements, 10(1), pp. 66-75. (doi: 10.1016/S1359-6349(12)70013-7)

Cowan, C.C., Hutchison, C., Cole, T., Barry, S.J.E. , Paul, J. , Reed, N.S. and Russell, J.M. (2012) A randomised double-blind placebo-controlled trial to determine the effect of cranberry juice on decreasing the incidence of urinary symptoms and urinary tract infections in patients undergoing radiotherapy for cancer of the bladder or cervix. Clinical Oncology, 24(2), e31-e38. (doi: 10.1016/j.clon.2011.05.009)

Penninckx, B., Van de Voorde, W.M., Casado, A., Reed, N., Moulin, C. and Karrasch, M. (2012) A systemic review of toxic death in clinical oncology trials: an Achilles’ heel in safety reporting revisited. British Journal of Cancer, 107(1), pp. 1-6. (doi: 10.1038/bjc.2012.252)

Viswanathan, A.N. et al. (2012) International brachytherapy practice patterns: a survey of the Gynecologic Cancer Intergroup (GCIG). International Journal of Radiation Oncology, Biology, Physics, 82(1), pp. 250-255. (doi: 10.1016/j.ijrobp.2010.10.030)

Cibula, D. et al. (2011) Training in bowel and upper abdominal surgery in gynaecological oncology. International Journal of Gynecological Cancer, 21(7), pp. 1264-1265. (doi: 10.1097/IGC.0b013e3182208141)

Kurtz, J. E. et al. (2011) Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study. Annals of Oncology, 22(11), pp. 2417-2423. (doi: 10.1093/annonc/mdr001)

Lee, C. K. et al. (2011) Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. British Journal of Cancer, 105(3), pp. 360-365. (doi: 10.1038/bjc.2011.256)

Medley, L., Morel, A. N., Farrugia, D., Reed, N., Hayward, N., Davies, J. M., Kirichek, O., Thakker, R.V. and Talbot, D. C. (2011) Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours. British Journal of Cancer, 104(7), pp. 1067-1070. (doi: 10.1038/bjc.2011.76)

Reed, N.S. and Harrand, R.L. (2011) Counterpoint: The role of adjuvant radiation in endometrial cancer. Inside, outside, or not at all? Brachytherapy, 10(1), pp. 4-6. (doi: 10.1016/j.brachy.2010.11.001)

Reed, N.S. and Harrand, R.L. (2011) Rebuttal to Drs. Nout and Creutzberg. Brachytherapy, 10(1), p. 8. (doi: 10.1016/j.brachy.2010.11.004)

Rustin, G. et al. (2011) A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer. Annals of Oncology, 22(11), pp. 2411-2416. (doi: 10.1093/annonc/mdq780)

Shrimali, R.K., Correa, P.D. and Reed, N.S. (2011) Dose-dense and dose-intense chemotherapy for small cell ovarian cancer: 2 cases and review of literature. Medical Oncology, 28(3), pp. 766-770. (doi: 10.1007/s12032-010-9509-0)

Vergote, I., Trope, C. G., Amant, F., Ehlen, T., Reed, N.S. and Casado, A. (2011) Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer. Journal of Clinical Oncology, 29(31), pp. 4076-4078. (doi: 10.1200/JCO.2011.36.9785)

Zweifel, M. et al. (2011) Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Annals of Oncology, 22(9), pp. 2036-2041. (doi: 10.1093/annonc/mdq708)

Vergote, I. et al. (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. New England Journal of Medicine, 363(10), pp. 943-953. (doi: 10.1056/NEJMoa0908806)

Reed, N.Z. et al. (2008) Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European organisation for research and treatment of cancer gynaecological cancer group study (protocol 55874). European Journal of Cancer, 44(6), pp. 808-818. (doi: 10.1016/j.ejca.2008.01.019)

This list was generated on Mon Sep 27 16:24:45 2021 BST.